Fangfang Li

609 total citations
29 papers, 410 citations indexed

About

Fangfang Li is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Fangfang Li has authored 29 papers receiving a total of 410 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Fangfang Li's work include Cancer Immunotherapy and Biomarkers (6 papers), Ferroptosis and cancer prognosis (3 papers) and Immunotherapy and Immune Responses (3 papers). Fangfang Li is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Ferroptosis and cancer prognosis (3 papers) and Immunotherapy and Immune Responses (3 papers). Fangfang Li collaborates with scholars based in China, Japan and France. Fangfang Li's co-authors include Guojun Zhang, Li‐Li Lou, Mengyuan Tian, Jingxia Chang, Hao Yang, Liang Zhao, Yang Zhang, Fanping Meng, Manabu Fujimoto and Hong‐Ling Gao and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Frontiers in Immunology.

In The Last Decade

Fangfang Li

27 papers receiving 409 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fangfang Li China 12 183 121 114 82 69 29 410
Xiaoyi Zhang China 12 161 0.9× 230 1.9× 90 0.8× 125 1.5× 66 1.0× 38 487
Marjan Taherian Iran 5 217 1.2× 141 1.2× 201 1.8× 83 1.0× 79 1.1× 10 525
Kalliopi Domvri Greece 12 231 1.3× 113 0.9× 146 1.3× 108 1.3× 48 0.7× 18 430
Mojgan Esparvarinha Iran 7 254 1.4× 152 1.3× 205 1.8× 103 1.3× 64 0.9× 9 580
Tomas Koltai Italy 10 225 1.2× 198 1.6× 116 1.0× 70 0.9× 50 0.7× 24 456
Haofan Wang China 10 186 1.0× 97 0.8× 114 1.0× 61 0.7× 61 0.9× 19 392
Hengxing Chen China 13 309 1.7× 120 1.0× 149 1.3× 69 0.8× 66 1.0× 19 516
Asieh Emami Nejad Iran 4 228 1.2× 140 1.2× 207 1.8× 78 1.0× 59 0.9× 5 499
Ping Mei China 11 251 1.4× 114 0.9× 153 1.3× 53 0.6× 73 1.1× 37 421

Countries citing papers authored by Fangfang Li

Since Specialization
Citations

This map shows the geographic impact of Fangfang Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fangfang Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fangfang Li more than expected).

Fields of papers citing papers by Fangfang Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fangfang Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fangfang Li. The network helps show where Fangfang Li may publish in the future.

Co-authorship network of co-authors of Fangfang Li

This figure shows the co-authorship network connecting the top 25 collaborators of Fangfang Li. A scholar is included among the top collaborators of Fangfang Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fangfang Li. Fangfang Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Li, Fangfang, et al.. (2024). scRNA-Seq and Bulk-Seq Analysis Identifies S100A9 Plasma Cells as a Potentially Effective Immunotherapeutic Agent for Multiple Myeloma. Journal of Inflammation Research. Volume 17. 1527–1548. 1 indexed citations
3.
Bai, Meirong, Fangfang Li, Jiamei Wang, et al.. (2024). Macrophage P2Y12 regulates iron transport and its inhibition protects against atherosclerosis. Journal of Advanced Research. 76. 585–603. 2 indexed citations
4.
Pei, Wenjing, Si Li, Fangfang Li, et al.. (2024). Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response. Bioorganic Chemistry. 150. 107539–107539. 12 indexed citations
5.
6.
Wang, Zhiyuan, Weizhou Wang, Xiaofang Wang, et al.. (2023). Multi-omics analysis of LAMB3 as a potential immunological and biomarker in pan-cancer. Frontiers in Molecular Biosciences. 10. 1157970–1157970. 8 indexed citations
7.
Lu, Wei‐Yu, Biao Xie, Jingyi Ren, et al.. (2023). Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer. Frontiers in Endocrinology. 14. 1088944–1088944. 3 indexed citations
8.
Zhao, Zhiyong, Zhongwei Zhang, Jing Liu, et al.. (2023). Supine transfer test-induced changes in cardiac index predict fluid responsiveness in patients without intra-abdominal hypertension. BMC Anesthesiology. 23(1). 318–318. 1 indexed citations
9.
Yuan, Yuan, Hongxia Xia, Zhaopeng Wang, et al.. (2023). OSMR deficiency aggravates pressure overload-induced cardiac hypertrophy by modulating macrophages and OSM/LIFR/STAT3 signalling. Journal of Translational Medicine. 21(1). 290–290. 6 indexed citations
10.
Zhang, Zhongwei, Shan Zhang, Qian Xing, et al.. (2023). Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis. Journal of Cancer Research and Clinical Oncology. 149(10). 8019–8026. 6 indexed citations
11.
Xing, Qian, et al.. (2022). Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib. Frontiers in Immunology. 13. 944013–944013. 12 indexed citations
12.
Liu, Hao, Fangfang Li, Ruiping Zheng, et al.. (2022). Structural and Functional Brain Changes in Patients With Classic Trigeminal Neuralgia: A Combination of Voxel-Based Morphometry and Resting-State Functional MRI Study. Frontiers in Neuroscience. 16. 930765–930765. 11 indexed citations
13.
Tao, Haitao, Fangfang Li, Qingyan Liu, et al.. (2022). Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer. Translational Lung Cancer Research. 11(3). 381–392. 12 indexed citations
14.
Li, Fangfang, Enoch Appiah Adu‐Gyamfi, Xuemei Chen, et al.. (2021). Downregulation of fascin in the first trimester placental villi is associated with early recurrent miscarriage. Experimental Cell Research. 403(1). 112597–112597. 12 indexed citations
15.
Qiu, Lingxiao, Pan Song, Huaqi Wang, et al.. (2021). Clinical Characteristics and Prognosis of Patients With Pulmonary Mucoepidermoid Carcinoma: A SEER-Based Analysis. Frontiers in Oncology. 11. 601185–601185. 11 indexed citations
16.
Fujimoto, Manabu, Fangfang Li, Ran Yu, et al.. (2021). Dihydroartemisinin Alleviates Imiquimod-Induced Psoriasis-like Skin Lesion in Mice Involving Modulation of IL-23/Th17 Axis. Frontiers in Pharmacology. 12. 704481–704481. 16 indexed citations
17.
Yang, Hao, Liang Zhao, Yang Zhang, & Fangfang Li. (2021). A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma. Cancer Medicine. 10(16). 5696–5711. 33 indexed citations
18.
Tao, Haitao, Fangfang Li, Ruixin Li, Han Xiao, & Yi Hu. (2020). Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report. Annals of Palliative Medicine. 9(5). 3623–3628. 4 indexed citations
19.
Li, Fangfang, Hao Yang, Shanshan Chen, et al.. (2020). PGAM1, regulated by miR-3614-5p, functions as an oncogene by activating transforming growth factor-β (TGF-β) signaling in the progression of non-small cell lung carcinoma. Cell Death and Disease. 11(8). 710–710. 30 indexed citations
20.
Su, Li, Yongli Luo, Zhi Yang, et al.. (2016). MEF2D Transduces Microenvironment Stimuli to ZEB1 to Promote Epithelial–Mesenchymal Transition and Metastasis in Colorectal Cancer. Cancer Research. 76(17). 5054–5067. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaoyi Zhang Breakdown of academic impact, for papers by Marjan Taherian Breakdown of academic impact, for papers by Kalliopi Domvri Breakdown of academic impact, for papers by Mojgan Esparvarinha Breakdown of academic impact, for papers by Tomas Koltai Breakdown of academic impact, for papers by Haofan Wang Breakdown of academic impact, for papers by Hengxing Chen Breakdown of academic impact, for papers by Asieh Emami Nejad Breakdown of academic impact, for papers by Ping Mei
Rankless by CCL
2026